ArticleHealth science reports2018

Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial.

Almasa Bass et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.